Set of STR-markers for 6p21.31 chromosomal region linkage analysis and CNV study

N. V. Hryshchenko¹, O. P. Kirichenkova², V. V. Gordiyk¹, S. A. Kravchenko¹, V. I. Kashuba¹,³

¹ Institute of Molecular Biology and Genetics, NAS of Ukraine
150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143
² Educational and Scientific Center "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv
64/13, Volodymyrska Str., Kyiv, Ukraine, 01601
³ Karolinska Institutet
Stockholm SE-171 77, Sweden
n.v.hryshchenko@imbg.org.ua

The aim of the study is to create a panel of informative STR-markers in HLA locus for the analysis of genomic rearrangements in different types of malignant tumors as well as for the selection of the HLA matched sibling for allogeneic transplantation. Methods. The preliminary screening of six presumed STR-markers located in the proximal, central and distal parts of the HLA chromosome region (6p21.31) was performed by agarose gel electrophoresis of the PCR-fragments. The accurate genotyping of the most promising STR-markers was carried out by electrophoretic separation of the PCR-fragments in a polyacrylamide gel on an automatic laser analyzer. Results. Based on the obtained results we have selected three STRs with the highest heterozygosity indexes (HI): D6S2678 – HLA class I (HI=91.4 %), DQIV – class II (HI=62.8 %) and D6S2925 – class III (HI=74.3 %) as potential markers for linkage and CNV study. Conclusion. We have demonstrated that the selected panel of markers allows us to effectively solve both tasks: detection of somatic rearrangements in different parts of HLA locus in tumor samples and HLA-haplotype determination to select a suitable related donor for transplantation.

Keywords: STR-marker, HLA-haplotype, allogeneic transplantation, cancer, somatic rearrangement.

Introduction

HLA (Human Leukocyte Antigens) on the short arm of chromosome 6 (6p21.31, 4 million base pairs) encode cell surface glycoproteins of human Major Histocompatibility
Complex (MHC). More than 200 HLA-genes are organized into 3 chromosome loci according to the functions of expressed antigens (class I-III). MHC proteins are involved in inducing and regulation of human immune response. The class I proteins form the complex with an antigen for recognition by cytotoxic CD8+ T cells and are also involved in the initiation of transplant immunity. The class II molecules represent an antigen to CD4+ T-helpers and CD4+ T-inflammation cells and initiate the transplant immunity. The class III genes encode SS and SLP complement proteins and TNF-α and TNF-β cytokines.

It is known that an increased rate of somatic rearrangements such as CNV (Copy Number Variations) leading to deletion and duplications in the HLA genes is one of the possible mechanisms of immune evasion in the development and progression of some types of cancers [1-3]. On the other hand, HLA haplotypes allow the selection of siblings that are HLA matched with a patient who is in need of an allogeneic transplantation [4]. Because of the 25 % probability of a sibling to inherit the same alleles of HLA locus as the patient, the favorable outcome of such transplantation is much higher than the selection by HLA phenotypes of a partially HLA-mismatched donor.

The short tandem repeat (STR) polymorphisms are the DNA-regions consisting of a polymorphic number of 2-6 nucleotides’ units, which occur frequently in the human genome and are widely used in different molecular diagnostic applications (parentage identification, linkage studies, germline and somatic deletion/duplication identification and others) [5]. The main diagnostic characteristics of STRs are their heterozygosity indexes and the number of different alleles in the studied population. Therefore, to choose the panel of the most informative diagnostic STRs, the genetic characterization of the chosen DNA-markers is needed.

The aim of the study is to create a panel of informative STR-markers from three regions of the HLA locus for the analysis of genomic rearrangements in different types of malignant tumors as well as for selection of the HLA matched sibling for allogeneic transplantation.

Patients and Methods

The objects of our study are the DNA samples from blood leucocytes of 35 healthy volunteers, the members of 10 core families (both parents and children with confirmed biological paternity status) and from the surgical material of 15 patients with ovarian tumors. The DNA samples used in the current study were taken from the previously collected DNA biobank [6-7]. All participants involved in the DNA biobanking gave the informed consent to participate in the research studies.

For STR genotyping of the samples, PCR followed by fragment analysis was used. The preliminary analysis of six previously published STR-markers from HLA locus [8-9] was performed using 2 % agarose gel for the separation of STR-alleles. The most polymorphic markers were selected for further analysis. One of the PCR-primers for each selected STR-marker amplification was labeled by Cy5 fluorescent dye fabricated by Methabion, Germany. PCR mixture (15μl) contained 1x FIREPol® Master Mix Ready to Load with 7.5mM MgCl₂ (Solis BioDyne), 60 μmol primers and 300 ng of gDNA. PCR was carried
Set of STR-markers for 6p21.31 chromosomal region linkage analysis and CNV study

out on 9200 Thermal Cycler (Applied Biosystems), 30 cycles, 60°C – annealing temperature. The fragment analysis of the STR-markers was carried out by electrophoretic separation of the PCR products in a 7 % de-naturated polyacrylamide gel on the automatic laser analyzer ALF-express II (Pharmacia Biotech). The allele discrimination and allelic imbalance were analyzed using ALF-express Fragment Manager Software.

The study of genomic rearrangements in the HLA region was performed using LOH analysis of the STR-markers. The marker was informative for the LOH-study if the patient’s normal sample was heterozygous of this marker. The limits of LOH value according to international recommendations were 0.67 > AI > 1.35 (AI – allelic imbalance). HLA haplotype linkage analysis of families was performed for all family members (mother, father, and two or more siblings), in order to identify the informative STR markers to detect the HLA haplotypes of each family member. The STR marker was considered to be informative when both parents were heterozygous for this marker, and the STR-alleles differed in size in mother and father. In the case where parents were heterozygous for the same alleles, the marker was considered informative if the recipient child was a homozygote for either of the two parental alleles.

Results and Discussion
We tested 6 STR-markers (2 each in proximal, central and distal areas of HLA-locus) on the DNA samples of conventionally normal individuals from Ukraine. According to the results of fragment analysis in agarose gel, 3 potential markers for the study of their informativeness were selected: D6S2678 (class I), DQIV (class II) and D6S2925 (class III), which according to preliminary data had the highest heterozygosity indexes. To determine the exact size of PCR-products of the STR-markers se-

![Fig.1. An example of allelic distribution of the marker D6S2678, ALF-fluorogram of the PCR products](image-url)
Selected in the previous step, the analysis was performed using ALF express II (fig. 1).

Based on the results of the analysis of 35 unrelated DNA samples, the heterozygosity index of each STR-marker was determined (Table 1). The selected STRs have been characterized by the allele variety and the level of heterozygosity in the studied group.

A large number of alleles and high heterozygosity indexes indicate that the selected STR-markers are highly informative for both LOH HLA-analysis and linkage HLA-haplotype analysis.

Using the selected panel of markers, the preliminary HLA-haplotype analysis in several core families (parents and children) and LOH anal-

---

**Table 1. Diagnostic characteristics of the STR-markers of HLA-region**

| Marker      | HLA locus and genes | N of alleles | HI       |
|-------------|---------------------|-------------|----------|
| D6S2678     | Class I: HLA-E – HLA-C | 12          | 91.4 %   |
| DQIV        | Class II: DQB1–DOB  | 9           | 62.8 %   |
| D6S2925     | Class III: HLA-B–MICB | 11          | 74.3 %   |

HI – Heterozygosity Index

**Fig. 2.** Linkage analysis of HLA-haplotypes of D6S2925 and D6S2678 STR-markers: 1 – proband, 2 – mother, 3 – father, 4 – sibs. The proband and his sibling inherited the same HLA-haplotype from their father and different HLA-haplotypes from their mother.
sis in paired samples of ovarian tumor tissue (tumor-normal) were carried out. The examples of both types of analyzes are shown in figures 2 and 3. The shown cases were fully informative.

**LOH-analysis:**

AR (allele ratio) – ratio of the intensity of the alleles in 1 sample:

\[
AR = \frac{S_{\text{allele1}}}{S_{\text{allele2}}};
\]

S – peak area of the allele

AI (allelic imbalance) – ratio of AR values of normal and tumor sample of the patient:

\[
AI = \frac{AR_{\text{normal}}}{AR_{\text{tumor}}}
\]

The HLA-haplotype analysis revealed that the sibling could not be the fully matched donor to the patient as far as he inherited different HLA-alleles from mother by both STR-markers. So, the offsprings in the current family are partial HLA-matched relatives. Noteworthy, the HLA region is a hot spot of genomic rearrangements. Thus, to predict the crossing-over events and avoid misdiagnosis in a linkage analysis, we used 3 markers from different parts of the HLA-region. This allows us to determine the HLA haplotype that is inherited from mother and father by each child even in the case of crossing-over.

LOH-analysis detects partial deletion in HLA class III region in 2 out of 3 shown ovarian tumors (ov15 and ov23). In the studied group of 15 patients with ovarian cancer, 8 partial deletions of at least one of the studied HLA-loci were identified. Thus, we may pre-

![Fig. 3. ALF-fluorogram of PCR-fragments of D6S2925 in patients with ovarian cancer: 1, 3, 5 – tumor samples of the patients ov15, ov22 and ov23; 2, 4, 6 – the corresponding samples of normal tissues. AI(ov15)= 3.7; AI(ov22)= 0.9; AI(ov23)= 9.2.](image-url)
dict that these patients would have an incorrect response to immunotherapy due to impaired inflammatory processes [10]. However, to confirm this hypothesis, further research is needed in an enlarged group of patients as well as an analysis of expression of HLA-genes located in the somatic deletions’ region.

Conclusions

The analysis using the D6S2678 (class I), DQIV (class II) and D6S2925 (class III) STR markers allows us to determine the somatic rearrangements of the HLA region in malignant tumors, which could be used to predict the immunotherapy effectiveness and treatment outcome in cancer patients. The current panel of markers could also be used to detect HLA matched sibling for allogeneic transplantation. This method is highly informative, inexpensive, and low labor-intensive; therefore, it could be recommended for a routine diagnostics.

REFERENCES

1. Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582-587.
2. Doonan BP, Haque A. Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design. J Clin Cell Immunol. 2015;6(4). pii: 351.
3. Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Pattn E, Thorball CW, Chaturvedi N, Charbit B, Abel L, Quintana-Murci L, Duffy D, Albert ML, Fellay J; Milieu Intérieur Consortium. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018;10(1):59.
4. Howard CA, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, Horowitz MM, Mendizabal A, Laport GG, Pasquini MC, Spellman SR. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2015;21(1):4-7.
5. Willems T, Gymrek M, Highnam G; 1000 Genomes Project Consortium, Mittelman D, Erlich Y. The landscape of human STR variation. Genome Res. 2014;24(11):1894-904.
6. Kashuba V, Dmitriev AA, Krasnov GS, Pavlova T, Ignatiev I, Gordiyuk VV, Gerashchenko AV, Braga EA, Yenamandra SP, Lerman M, Senchenko VN, Zabarovsky E. NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer. Int J Mol Sci. 2012;13(10):13352-77.
7. Fesai OA, Kravchenko SA, Tirkus MY, Makukh GV, Zinchenko VM, Strelko GV, Livshits LA. CAG polymorphism of the androgen receptor gene in azoospermic and oligozoospermic men from Ukraine. Cytol Genet. 2009;43:401–5.
8. Bick SL, Bick DP, Wells BE, Roesler MR, Strawn EY, Lau EC. Preimplantation HLA haplotyping using tri-, tetra-, and pentanucleotide short tandem repeats for HLA matching. J Assist Reprod Genet. 2008;25(7):323-31.
9. Cullen M, Malasky M, Harding A, Carrington M. High-density map of short tandem repeats across the human major histocompatibility complex. Immunogenetics. 2003;54(12):900-10.
10. Deakin JE, Papenfuss AT, Belov K, Cross JG, Coggill P, Palmer S, Sims S, Speed TP, Beck S, Graves JA. Evolution and comparative analysis of the MHC Class III inflammatory region. BMC Genomics. 2006;7:281.
будов при різних типах злоякісних пухлин, а також для вибору HLA-суспісного спорідненого донора для алогенних трансплантацій. **Методи.** Попередній скринінг шести передбачуваних STR-маркерів, розташованих в проксимальному, центральному та дистальному відділах хромосомної області HLA (6p21.31), проводили за допомогою електрофорезу ПЛР-фрагментів в агарозному гелі. Точне генотипування найбільш перспективних STR-маркерів проводилося шляхом електрофоретичного фракціонування ПЛР-фрагментів в поліакриламідному гелі на автоматичному лазерному аналізаторі. **Результати.** На підставі отриманих результатів відібрано три STR-локуси з найвищими індексами гетерозиготності (ІГ): D6S2678 – HLA класу I (ІГ = 91,4 %), DQIV – класу II (ІГ = 62,8 %) і D6S2925 – класу III (ІГ = 74,3 %) в якості потенційних маркерів для дослідження внутрісімейного зчеплення і аналізу CNV. **Висновки.** Продемонстровано, що обрана панель маркерів дозволяє ефективно вирішувати обидва завдання: виявлення соматичних реорганізацій в різних ділянках локусу HLA в зразках пухлин і визначення HLA-гаплотипу для вибору підходящого родинного донора для трансплантації.

**Ключові слова:** STR-маркер, HLA-гаплотип, алогенна трансплантація, рак, соматична реорганізація.

**Панель STR-маркеров для анализа сцепления и CNV хромосомной области 6p21.31**

Н. В. Грищенко, А. П. Кириченкова, В. В. Гордиюк, С. А. Кравченко, В. И. Кашуба

Целью исследования является создание панели информативных STR-маркеров локуса HLA для анализа геномных перестроек при различных типах злокачественных опухолей, а также для выбора HLA-совместимого родственного донора для алогенной трансплантации. **Методы.** Предварительный скрининг шести предполагаемых STR-маркеров, расположенных в проксимальном, центральном и дистальном отделах хромосомной области HLA (6p21.31), проводили с помощью электрофореза ПЦР-фрагментов в агарозном геле. Точное генотипирование наиболее перспективных STR-маркеров проводилось электрофоретическим разделением ПЦР-фрагментов в полиакриламидном геле на автоматическом лазерном анализаторе. **Результаты.** На основании полученных результатов мы отобрали три STR-локуса с наивысшими индексами гетерозиготности (ИГ): D6S2678 – HLA класса I (ИГ = 91,4 %), DQIV – класса II (ИГ = 62,8 %) и D6S2925 – класса III (ИГ = 74,3 %) в качестве потенциальных маркеров для исследования внутрисемейного сцепления и анализа CNV. **Выводы.** Продемонстрировано, что выбранная панель маркеров позволяет эффективно решать обе задачи: обнаружение соматических реорганізаций в различных участках локуса HLA в образцах опухолей и определение HLA-гаплотипа для выбора подходящего родственного донора для трансплантации.

**Ключевые слова:** STR-маркер, HLA-гаплотип, алогенная трансплантація, рак, соматична реорганізація.

Received 15.03.2019